PhD, MSc, BSc
Senior Clinical Trials Project Manager
I joined OVG in December 2021 as a Project manager to ensure that the clinical trials are delivered on time, within budget and in compliance with the regulatory requirements. I manage the set up and delivery of non-commercial and commercial, University of Oxford- or externally-sponsored, adult and paediatric vaccine clinical trials.
Before joining OVG, from 2008 till 2013 I was a scientist at the Cell Differentiation and Tumorigenesis research group headed by Prof Achim Leutz and was awarded a PhD fellowship from the International PhD Program at Max Delbruck Center for Molecular Medicine and Humboldt University, Berlin, Germany.
After completing my PhD, I worked as a postdoctoral researcher at Prof Paresh Vyas research group Biology and Treatment of Human Myeloid Cancers at the MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine. I worked on research projects aiming to understand the mechanisms of blood cell development and how these mechanisms get deregulated in leukaemia.
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Jakobsen NA. et al, (2023)
A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies.
Lachowiez CA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.
Juban G. et al, (2021), Haematologica, 106, 1106 - 1119
Mechanisms of Response and Resistance to AML Therapies.
Stoilova B. et al, (2020), Clin Lymphoma Myeloma Leuk, 20 Suppl 1
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax plus /- azacitidine in IDH1-mutated hematologic malignancies.
Lachowiez CA. et al, (2020), JOURNAL OF CLINICAL ONCOLOGY, 38